Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Acute Kidney Injury D058186 34 associated lipids
Airway Remodeling D056151 3 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypoalphalipoproteinemias D052456 5 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Cholecystitis, Acute D041881 1 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Best LC et al. The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro. 1980 Thromb. Haemost. pmid:6773171
Miller KW and Keith JC Effect of thromboxane synthetase inhibition on platelet function and morphology during ovine pregnancy-induced hypertension. 1988 Thromb. Haemost. pmid:3238644
Joseph S et al. Effect of the polyamine-spermine on agonist-induced human platelet activation--specific inhibition of "aggregation-independent" events induced by thrombin, but not by collagen, thromboxane mimetic, phorbol ester or calcium ionophore. 1987 Thromb. Haemost. pmid:3110996
Hansen JB et al. The effect of lipopolysaccharides (LPS) on generation of thromboxane A2 and thromboplastin activity in whole blood of males, females and females on oral contraceptives. 1989 Thromb. Haemost. pmid:2799762
Siess W et al. Stimulated platelet aggregation, thromboxane B2 formation and platelet sensitivity to prostacyclin - a critical evaluation. 1981 Thromb. Haemost. pmid:7025338
Watanabe J et al. Effect of vitamin E on platelet aggregation in diabetes mellitus. 1984 Thromb. Haemost. pmid:6495252
Matsumoto M et al. Thromboxane generation in patients with essential hypertension or cerebrovascular disease and effect of oral aspirin. 1980 Thromb. Haemost. pmid:7423441
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Gresele P et al. Picotamide protects mice from death in a pulmonary embolism model by a mechanism independent from thromboxane suppression. 1990 Thromb. Haemost. pmid:2274931
Scharf RE In vitro thromboxane synthesis of depleted blood platelets following renal transplantation. 1990 Thromb. Haemost. pmid:2148845
Hoet B et al. Ridogrel, a combined thromboxane synthase inhibitor and receptor blocker, decreases elevated plasma beta-thromboglobulin levels in patients with documented peripheral arterial disease. 1990 Thromb. Haemost. pmid:2148849
Cattaneo M et al. Human platelet aggregation and release reaction induced by platelet activating factor (PAF-acether)--effects of acetylsalicylic acid and external ionized calcium. 1985 Thromb. Haemost. pmid:3927505
Crescente M et al. Gallic acid, a dietary polyphenolic component, blunts the inhibition of platelet COX-1 by aspirin: preliminary in-vitro findings. 2007 Thromb. Haemost. pmid:17549313
Undas A et al. Lack of aspirin-induced decrease in thrombin formation in subjects resistant to aspirin. 2007 Thromb. Haemost. pmid:17549314
Perneby C et al. Dose- and time-dependent antiplatelet effects of aspirin. 2006 Thromb. Haemost. pmid:16601836
Hampton KK et al. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo. 1990 Thromb. Haemost. pmid:2073296
Dragani A et al. Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. 2012 Thromb. Haemost. pmid:22782530
Gordge MP et al. Platelet function and the bleeding time in progressive renal failure. 1988 Thromb. Haemost. pmid:3187950
D'Angelo A et al. Effect of des-amino-D-arginine vasopressin (DDAVP) on plasma levels of platelet and endothelial cell release products. 1983 Thromb. Haemost. pmid:6687766
Vezza R et al. Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism. 1997 Thromb. Haemost. pmid:9408024
Han P et al. Verapamil and collagen-induced platelet reactions--evidence for a role for intracellular calcium in platelet activation. 1983 Thromb. Haemost. pmid:6415847
Guthikonda S et al. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. 2008 Thromb. Haemost. pmid:18612542
Gresele P et al. Platelet activation markers in patients with peripheral arterial disease--a prospective comparison of different platelet function tests. 1997 Thromb. Haemost. pmid:9423790
Naesh O et al. Platelet function in surgical stress. 1985 Thromb. Haemost. pmid:2935969
Davì G et al. The effect of two low doses of aspirin on whole blood thromboxane and prostacyclin generation in healthy subjects. 1983 Thromb. Haemost. pmid:6417815
Michelson AD et al. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. 1994 Thromb. Haemost. pmid:7522354
Hornby EJ et al. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion. 1989 Thromb. Haemost. pmid:2529661
Husted SE et al. Intravenous acetylsalicylic acid--dose-related effects on platelet function and fibrinolysis in healthy males. 1992 Thromb. Haemost. pmid:1412171
Subbiah MT et al. Studies of aggregation and thromboxane B2 synthesis in avian thrombocytes: comparison between atherosclerosis-susceptible and resistant breeds. 1980 Thromb. Haemost. pmid:7455983
Halawani SH et al. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. 2011 Thromb. Haemost. pmid:21544317
Patrono C et al. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. 1995 Thromb. Haemost. pmid:8578493
Cortellaro M et al. Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis-effect of sulphinpyrazone treatment. 1983 Thromb. Haemost. pmid:6665767
Szczeklik A et al. Prolonged bleeding time, reduced platelet aggregation, altered PAF-acether sensitivity and increased platelet mass are a trait of asthma and hay fever. 1986 Thromb. Haemost. pmid:3563961
Falcon CR et al. The in vitro production of thromboxane B2 by platelets of diabetic patients is normal at physiological concentrations of ionized calcium. 1993 Thromb. Haemost. pmid:8259535
Fruzzetti F et al. Platelet-vessel wall interactions with third-generation oral contraceptives: no evidence of detrimental effects. 1999 Thromb. Haemost. pmid:10494782
Cattaneo M et al. Conditions influencing the interaction of asialo von Willebrand factor with human platelets--the effects of external ionized calcium concentration and the role of arachidonate pathway. 1988 Thromb. Haemost. pmid:3146144
Fimognari FL et al. Nocturnal rise of urinary thromboxane B 2 in patients with coronary artery disease. 2005 Thromb. Haemost. pmid:15735822
De Caterina R et al. Organic nitrates: direct antiplatelet effects and synergism with prostacyclin. Antiplatelet effects of organic nitrates. 1988 Thromb. Haemost. pmid:3291182
Teng CM and Ko FN Comparison of the platelet aggregation induced by three thrombin-like enzymes of snake venoms and thrombin. 1988 Thromb. Haemost. pmid:3291184
de Castellarnau C et al. Prostacyclin and thromboxane production by autogenous femoral veins grafted into the arterial circulation of the dog. 1989 Thromb. Haemost. pmid:2665174
Davì G et al. Demonstration of Rickettsia Conorii-induced coagulative and platelet activation in vivo in patients with Mediterranean spotted fever. 1995 Thromb. Haemost. pmid:8584998
Habib A et al. Increased expression of inducible cyclooxygenase-2 in human endothelial cells by antiphospholipid antibodies. 1995 Thromb. Haemost. pmid:8585020
Evangelista V et al. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes. 1992 Thromb. Haemost. pmid:1509406
Pettinella C et al. Cyclooxygenase-1 haplotype C50T/A-842G does not affect platelet response to aspirin. 2009 Thromb. Haemost. pmid:19350112
Totani L et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. 2012 Thromb. Haemost. pmid:22436970
Véricel E et al. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients. 2015 Thromb. Haemost. pmid:25832443
Spowart K et al. Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. 1988 Thromb. Haemost. pmid:3266379
Cerletti C et al. Aspirin kinetics and inhibition of platelet thromboxane generation-relevance for a solution of the "aspirin dilemma". 1985 Thromb. Haemost. pmid:4049312
Dotevall A et al. Cigarette smoking increases thromboxane A2 formation without affecting platelet survival in young healthy females. 1992 Thromb. Haemost. pmid:1455405
de Boer A et al. Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. 1991 Thromb. Haemost. pmid:1722918
Davì G et al. Influence of metabolic control on thromboxane biosynthesis and plasma plasminogen activator inhibitor type-1 in non-insulin-dependent diabetes mellitus. 1996 Thromb. Haemost. pmid:8819248
Forastiero R et al. Anti-beta2 glycoprotein I antibodies and platelet activation in patients with antiphospholipid antibodies: association with increased excretion of platelet-derived thromboxane urinary metabolites. 1998 Thromb. Haemost. pmid:9459320
Carter AJ and Hanley SP The effect of platelet number and haematocrit on whole blood thromboxane synthesis. 1985 Thromb. Haemost. pmid:4024033
Schorer AE Discordant effects on eicosanoids and fibrin degradation products in two murine models of antiphospholipid antibody. 1997 Thromb. Res. pmid:9062953
Watanabe T et al. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis. 2001 Thromb. Res. pmid:11672751
Carroll RC et al. Post interventional cardiology urinary thromboxane correlates with PlateletMapping detected aspirin resistance. 2010 Thromb. Res. pmid:19962724
Ziegler BK et al. Incomplete thromboxane inhibition with 100 mg of intravenous acetylsalicylic acid in patients with acute ST elevation myocardial infarction: a placebo-controlled pilot trial. 2001 Thromb. Res. pmid:11672759
Ersöz G et al. The effect of submaximal exercise on platelet aggregation during late follicular and midluteal phases in women. 2002 Thromb. Res. pmid:12590951
Kawamura M et al. Evaluation of plasma 11-dehydro-thromboxane B2 as an indicator for thromboxane A2 synthesis in vivo in laboratory animals. 1995 Thromb. Res. pmid:7778061
Ersöz G et al. Effect of sodium selenite treatment on platelet aggregation of streptozotocin-induced diabetic rats. 2003 Thromb. Res. pmid:14698654
Teng CM et al. Two antiplatelet agents from Magnolia officinalis. 1988 Thromb. Res. pmid:3413728
Addonizio VP et al. Inhibition of human platelet function by verapamil. 1982 Thromb. Res. pmid:7164035
Vargaftig BB et al. Adrenaline and PAF-acether synergize to trigger cyclooxygenase-independent activation of plasma-free human platelets. 1982 Thromb. Res. pmid:7164036
Vlodavsky I et al. Platelet interaction with the extracellular matrix produced by cultured endothelial cells: a model to study the thrombogenicity of isolated subendothelial basal lamina. 1982 Thromb. Res. pmid:7179215
Cholette JM et al. Aspirin resistance following pediatric cardiac surgery. 2010 Thromb. Res. pmid:20550971
Umemura K et al. Effect of dietary docosahexaenoic acid in the rat middle cerebral artery thrombosis model. 1995 Thromb. Res. pmid:7660354
Carter AJ et al. Human pulmonary vessels obtained from necropsy produce less prostacyclin and thromboxane than fresh vessels obtained from operations. 1984 Thromb. Res. pmid:6547546
Rousson D et al. Acute myocardial infarction: measurement of arachidonate end-products in whole blood as an index of platelet cyclo-oxygenase activity in vivo. 1987 Thromb. Res. pmid:3122356
Hanasaki K and Arita H Characterization of a new compound, S-145, as a specific TXA2 receptor antagonist in platelets. 1988 Thromb. Res. pmid:2839912
Navran SS et al. Human platelet activation by bacterial phospholipase C is mediated by phosphatidylinositol hydrolysis but not generation of phosphatidic acid: inhibition by a selective inhibitor of phospholipase C. 1984 Thromb. Res. pmid:6372157
Ishikawa Y et al. Effect of cytoplasmic pH on platelet activation by arachidonic acid. 1989 Thromb. Res. pmid:2499076
Lages B and Weiss HJ Inhibition of human platelet function in vitro and ex vivo by acetaminophen. 1989 Thromb. Res. pmid:2499947
Küster LJ et al. Mechanism of PAF-induced platelet aggregation in man. 1986 Thromb. Res. pmid:3764802
Reimers HJ et al. Impaired thromboxane synthesis in preactivated human blood platelets: agonist-specific, irreversible desensitization to thrombin. 1987 Thromb. Res. pmid:3126557
Mercer JB et al. The effect of short-term cold exposure on risk factors for cardiovascular disease. 1999 Thromb. Res. pmid:10418798
Perneby C et al. Prothrombotic responses to exercise are little influenced by clopidogrel treatment. 2004 Thromb. Res. pmid:15381386
Hall ER et al. The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits. 1982 Thromb. Res. pmid:6891109
Lukasik M et al. Aspirin treatment influences platelet-related inflammatory biomarkers in healthy individuals but not in acute stroke patients. 2011 Thromb. Res. pmid:21788065
Udvardy M et al. Alterations of primary haemostasis in mixed connective tissue disease (MCTD). 1991 Thromb. Res. pmid:1835548
Marasini B et al. Cigarette smoking and platelet function. 1986 Thromb. Res. pmid:3787563
Deckmyn H et al. Prostacyclin production by whole blood from children: impairment in the hemolytic uremic syndrome and excessive formation in chronic renal failure. 1983 Thromb. Res. pmid:6344317
Neiman J et al. Composition of platelet phosphatidylinositol and phosphatidylcholine after ethanol withdrawal. 1987 Thromb. Res. pmid:3603426
Vesterqvist O et al. Development of a GC-MS method for quantitation of 2,3-dinor-TxB2 and determinations of the daily urinary excretion rates in healthy humans. 1984 Thromb. Res. pmid:6695361
Todd MK et al. Effect of exercise intensity on 6-keto-PGF1 alpha, TXB2, and 6-keto-PGF1 alpha/TXB2 ratios. 1992 Thromb. Res. pmid:1615492
Dembinska-Kiec A et al. Ticlopidine and platelet function in healthy volunteers. 1992 Thromb. Res. pmid:1615496
Maguire ED and Wallis RB In vivo redirection of prostaglandin endoperoxides into 6-keto PGF1 alpha formation by thromboxane synthetase inhibitors in the rat. 1983 Thromb. Res. pmid:6689221
Ames PR et al. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. 2012 Thromb. Res. pmid:22521214
Vesterqvist O et al. In vivo production of thromboxane in acute human myocardial infarction: a preliminary study. 1985 Thromb. Res. pmid:3992528
Chiang TM and Kang AH The effect of platelet surface protein phosphorylation on collagen-platelet interaction. 1986 Thromb. Res. pmid:3810565
Hofmann D et al. Evidence for sustained platelet activation in patients with early postinfarction angina. 1993 Thromb. Res. pmid:8303651
Knapp HR et al. Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. 1988 Thromb. Res. pmid:3293263
Selley ML et al. The effect of cholesterol oxidation products on human platelet aggregation. 1996 Thromb. Res. pmid:8885139
Kritz H et al. Isradipine increases vascular prostaglandin I2-formation while the thromboxane B2-synthesis is diminished. 1995 Thromb. Res. pmid:8610276
Bergqvist D et al. The effect of inhibition of thromboxane synthesis in experimental thrombosis and hemostasis. 1985 Thromb. Res. pmid:3838828
Domoto DT et al. Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. 1991 Thromb. Res. pmid:1926064
Küster LJ and Frölich JC PAF-induced platelet aggregation and TXB2 formation. 1989 Thromb. Res. pmid:2922704
Antonino MJ et al. Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. 2010 Thromb. Res. pmid:19446864
Altman R et al. Why single daily dose of aspirin may not prevent platelet aggregation. 1988 Thromb. Res. pmid:3140408
Simmet T and Weide I Thromboxane and cysteinyl-leukotriene formation are differentially activated in spontaneously clotting whole human blood in vitro. 1991 Thromb. Res. pmid:1866709
Meyers KM et al. An evaluation of the arachidonate pathway of platelets from companion and food-producing animals, mink, and man. 1980 Thromb. Res. pmid:7209869